Drug Profile

Selinexor - Karyopharm Therapeutics

Alternative Names: ATG-010; CRM1-nuclear-export-inhibitor; KPT-330; NEXPOVIO; ONO 7705; Selinisso; TP-53; XPOVIO

Latest Information Update: 06 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Karyopharm Therapeutics
Developer Antengene Corporation; Cardiff University; Grupo Espanol de Investigacion en Sarcomas; Karyopharm Therapeutics; Menarini; Ono Pharmaceutical; Promedico; University of Texas Southwestern Medical Center
Class Acrylamides; Anti-infectives; Antineoplastics; Antivirals; Fluorinated hydrocarbons; Foot disorder therapies; Hydrazines; Pyrazines; Skin disorder therapies; Small molecules; Triazoles
Mechanism of Action Exportin 1 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Diffuse large B cell lymphoma; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Multiple myeloma; Myelofibrosis; Soft tissue sarcoma
New Molecular Entity Yes

Marketed Diffuse large B cell lymphoma; Multiple myeloma
Phase III Endometrial cancer; Liposarcoma; Myelofibrosis
Phase II/III Acute myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
Phase II Colorectal cancer; COVID 2019 infections; Malignant melanoma; Ovarian cancer; Peripheral T-cell lymphoma; Thrombocytopenia; Thymic epithelial tumour; Thymoma; Triple negative breast cancer
Phase I/II Gastrointestinal stromal tumours; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours
No development reported B-cell lymphoma; Cervical cancer; Chronic lymphocytic leukaemia; Extranodal NK-T-cell lymphoma; Glioma; HER2 positive breast cancer; Liver cancer; Neuroendocrine tumours; Osteosarcoma; Sepsis; Soft tissue sarcoma
Discontinued Cutaneous T-cell lymphoma; Diabetic foot ulcer; Gastric cancer; Glioblastoma; Oesophageal cancer; Prostate cancer; Rectal cancer; Richter's syndrome; Small cell lung cancer; Squamous cell cancer

24 Mar 2026 Karyopharm Therapeutics plans meeting with the US FDA to discuss data from the SENTRY trial in second half of 2026
24 Mar 2026 Karyopharm Therapeutics plans to file supplemental new drug application (sNDA) for Myelofibrosis in second half of 2026
24 Mar 2026 Efficacy and adverse events data from phase III clinical trial in Myelofibrosis released by Karyopharm Therapeutics

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com